Piramal Imaging to highlights new Florbetaben data at SNMMI 2013

India Infoline News Service | Mumbai |

Dr. Stephens’ presentation will highlightthe clinical experience with florbetaben which is based on more than 900 applications at imaging centers across the U.S., Europe, Japan and Australia.

Piramal Imaging announced that results from four studies evaluating the Company’s PET amyloid imaging agent (florbetaben F18*) will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver fromJune 8-12.
 
Additionally, Andrew Stephens, Vice President of Clinical Research and Development at Piramal Imaging will present an update and highlights on florbetaben PET imaging in clinical trials as part of SNMMI’s Emerging Technologies Session on Neurodegenerative Imaging on Monday, June 10 at 12:00 p.m. in the West Building, room 306. Dr. Stephens’ presentation will highlightthe clinical experience with florbetaben which is based on more than 900 applications at imaging centers across the U.S., Europe, Japan and Australia. The florbetaben development program comprises six phase 1 studies, two global, multicenter phase 2 studies, an MCI study with two year follow-up, and a global, multicenter histopathology phase 3 study.


“This year’s annual meeting marks an important time as we look to commercialize florbetaben,” said Dr. Stephens. “Our clinical presentations at SNMMI further highlight Piramal Imaging’s commitment to advance the early detection of Alzheimer’s disease as well as our research to develop investigational radiopharmaceuticals to address major clinical needs in oncology, specifically prostate cancer.”

Florbetabenis currently being reviewed by the Food and Drug Administration(FDA) and European Medicines Agency (EMA) for use in the visual detection of beta-amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.Presentations highlighting Florbetaben and the Company’s pipeline compounds include:

Florbetaben F18
Close to clinical routine phase 2 trial on florbetaben PET imaging of â-amyloid (Aâ) in lzheimer's disease (AD)[Abstract #299]
Scientific Paper Session (Oral) 
Neuroscience: Tau and Amyloid Imaging
Tuesday, June 11, 8:00 - 8:12 a.m., West Building, Room 215-216 

Reliability, reproducibility and efficacy of the 18F florbetaben â-amyloid PET scan visual assessment method as trained via a computer-based instructional tool [Abstract #300]

Scientific Paper Session (Oral) Neuroscience: Tau and Amyloid Imaging
Tuesday, June 11,  8:12 – 8:24 a.m., West Building, Room 215-216


Age-dependent 18-F florbetaben brain PET uptake in adults with Down's syndrome [Abstract #468]

Scientific Paper Session (Oral) Prediction of Cognitive Dysfunction and Multimodal Imaging 



Tuesday, June 11, 2:57 – 3:09 p.m., West Building, Room 215-216

Effects of a partial volume correction on [18F]florbetaben PET for the assessment of longitudinal â-amyloid load in APP-Swe mice [Abstract #1754]

Scientific Poster Session Poster Section: MTA II: Basic Science (Neurosciences) Posters

Tuesday, June 11, 2:45 p.m., West Building, Exhibit Hall A 


FEMPA F18

Increased in vivo binding of [18F]FEMPA to the 18-kDa translocator protein in Alzheimer`s disease [Abstract # 137]

Scientific Paper Session (Oral) INTEGRATED Session: Inflammation Imaging and Neurological Disease 


Monday, June 10, 10:24-10:36 a.m. West Building, Room 215-216

FSPG F18

Pilot clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate PET in patients with prostate cancer [Abstract # 285]

Scientific Paper Session (Oral) 
Prostate/GU1

Tuesday, June 11, 8:00 – 8:12 a.m., West Building, Room 221-222 

Characterization of physiological 18F-FSPG uptake in healthy volunteers and comparison to 18F-FDG[Abstract # 63]

Scientific Paper Session (Oral) Nuclear Oncology Council YIA Symposium 



Sunday, June 9, 4:30-4:42 p.m., West Building, Room 224 

PMPA (BAY 1075553)


PMPA (BAY 1075553) PET/CT in the detection of primary prostate cancer - Phase I study [Abstract # 1590]

Scientific Poster Session Poster Section: MTA I: Prostate/GU Posters Session Info: Meet the Author Poster Session I 

Monday, June 10, 2:30 p.m., West Building, Exhibit Hall A

 

Advertisements

  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.
welcome to iifl